UE
RPRX icon

Unisphere Establishment’s Royalty Pharma RPRX Stock Holding History

Unisphere Establishment’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-5,000,000
Closed -$132M – 64
2024
Q2 		$132M Hold
5,000,000
– – 1.33% 23
2024
Q1 		$152M Hold
5,000,000
– – 1.53% 20
2023
Q4 		$140M Buy
+5,000,000
New +$137M 1.45% 23

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Unisphere Establishment's RPRX Position: Q3 2024 in Review

Unisphere Establishment sold out of Royalty Pharma (RPRX) in Q3 2024, closing a stake of 5,000,000 shares — an estimated $132M sold.

Unisphere Establishment first reported a position in RPRX in Q4 2023 and held it in 3 quarters. The position peaked at $152M in Q1 2024. 395 funds tracked by Wall St. Rank hold RPRX as of Q3 2024.

  • Unisphere Establishment reported no remaining Royalty Pharma position as of Q3 2024 after selling out during the quarter.
  • Unisphere Establishment sold 5,000,000 Royalty Pharma shares in Q3 2024, an estimated $132M.
  • Unisphere Establishment first reported a position in Royalty Pharma in Q4 2023 and held it in 3 quarters.
  • Unisphere Establishment's Royalty Pharma position peaked at $152M in Q1 2024.
  • 395 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2024.

Based on Unisphere Establishment's 13F filing for Q3 2024, filed 14 Nov 2024.